Bedrijfsoverzicht
Electromed, Inc. is a specialized developer, manufacturer, and marketer of airway clearance therapy products designed to apply high frequency chest wall oscillation (HFCWO) for pulmonary care across the United States and international markets. The company operates within the healthcare sector, specifically focusing on the medical devices industry, which necessitates rigorous regulatory compliance and technological innovation to serve patients requiring respiratory support. Electromed operates at a scale characterized by a market capitalization of $201.17M, generating annual revenue of $68.86M while employing a workforce of 177 individuals. These valuation and revenue figures indicate a mid-cap company with a established revenue base that is supported by a lean operational structure, suggesting a focused business model where a relatively small employee count generates significant sales volume per capita. The company's position as a provider of the SmartVest airway clearance system establishes its niche in the specialized medical device landscape, where the combination of specific therapeutic technology and international distribution capabilities defines its market footprint.
Financiële gezondheid
The company reported a revenue of $68.86M over the trailing twelve months, resulting in a net income of $8.99M and an EBITDA of $12.88M, which highlights a cost structure where operating expenses and taxes consume approximately 86.9% of total revenue to arrive at the bottom line. The generation of $7.08M in free cash flow demonstrates that Electromed, Inc. possesses substantial financial flexibility to fund research and development, manage working capital needs, or potentially acquire complementary assets without relying on external financing. Profitability analysis reveals a gross margin of 78.2%, indicating highly efficient production and pricing power typical of proprietary medical device technology, while an operating margin of 19.2% and a profit margin of 13.1% reflect the significant fixed costs and overhead associated with R&D, marketing, and regulatory compliance in the healthcare sector. The balance sheet presents a conservative financial posture with $13.79M in cash and cash equivalents significantly exceeding total debt of $96,000, a disparity further underscored by a low debt-to-equity ratio of 0.21. Liquidity is exceptionally strong as evidenced by a current ratio of 4.86, indicating that the company holds nearly five times the current assets required to cover its short-term liabilities, thereby mitigating default risk even during periods of market stress. Management effectiveness is quantified by a return on equity of 20.2% and a return on assets of 13.6%, metrics that reveal the company is generating substantial returns on the capital invested by shareholders and the total asset base relative to its industry peers.
Waarderingsbeoordeling
Valuation multiples indicate that the market prices Electromed, Inc. at a trailing P/E ratio of 23.42 and a forward P/E of 39.54, suggesting that the market expects earnings to grow significantly in the coming years to justify the higher forward multiple. The price-to-book ratio stands at 4.40, which implies that the stock trades at a significant premium to its book value, reflecting investor confidence in the intangible assets, intellectual property, and growth potential of the airway clearance therapy business. Alternative valuation metrics such as a price-to-sales ratio of 2.92 and an EV/EBITDA of 14.44 provide context that the company is valued on the basis of its revenue generation and cash earnings power rather than just historical earnings. Regarding price metrics, the stock has historically traded between a 52-week high of $30.73 and a 52-week low of $17.73, and while the current price is not explicitly stated in the provided facts, the valuation metrics suggest a market consensus that values the company near the upper end of its recent historical range relative to its earnings potential. The company exhibits a beta of 0.32, which indicates that its stock price volatility is substantially lower than the broader market, offering a profile that may be less sensitive to general market fluctuations compared to larger-cap technology or healthcare stocks.
Growth & Income
Electromed, Inc. demonstrates robust expansion with a revenue growth rate of 16.3% year-over-year and an earnings growth rate of 45.5% year-over-year, indicating that the company's earnings are growing at a rate significantly faster than its revenue, which often implies improving operational leverage or cost efficiencies as sales scale. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning that all net income is retained within the business to fund reinvestment in the SmartVest system, expansion of the international footprint, or reduction of the minimal existing debt. The absence of a dividend yield and a 0.0% payout ratio confirms that Electromed prioritizes capital allocation toward organic growth initiatives and R&D over providing immediate income returns to shareholders. The overall growth and income profile is defined by aggressive earnings expansion and a reinvestment strategy typical of high-growth medical device companies in the early-to-mid stages of their commercial lifecycle.